Reactive oxygen species (ROS) are produced at low levels in mammalian cells by various metabolic processes, such as oxidative phosphorylation by the mitochondrial respiratory chain, NAD(P)H oxidases, and arachidonic acid oxidative metabolism. To maintain physiological redox balance, cells have endogenous antioxidant defenses regulated at the transcriptional level by Nrf2/ARE. Oxidative stress results when ROS production exceeds the cell's ability to detoxify ROS. Overproduction of ROS damages cellular components, including lipids, leading to decline in physiological function and cell death. Reaction of ROS with lipids produces oxidized phospholipids, which give rise to 4-hydroxynonenal, 4-oxo-2-nonenal, and acrolein. The brain is susceptible to oxidative damage due to its high lipid content and oxygen consumption. Neurodegenerative diseases (AD, ALS, bipolar disorder, epilepsy, Friedreich's ataxia, HD, MS, NBIA, NPC, PD, peroxisomal disorders, schizophrenia, Wallerian degeneration, Zellweger syndrome) and CNS traumas (stroke, TBI, SCI) are problems of vast clinical importance. Free iron can react with H2O2via the Fenton reaction, a primary cause of lipid peroxidation, and may be of particular importance for these CNS injuries and disorders. Cholesterol is an important regulator of lipid organization and the precursor for neurosteroid biosynthesis. Atherosclerosis, the major risk factor for ischemic stroke, involves accumulation of oxidized LDL in the arteries, leading to foam cell formation and plaque development. This review will discuss the role of lipid oxidation/peroxidation in various CNS injuries/disorders. Antioxid Redox Signal. 12, 125–169.
AdibhatlaRM, HatcherJF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res, 73:308–315. 2003.
2.
AdibhatlaRM, HatcherJF. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res, 30:15–23. 2005.
3.
AdibhatlaRM, HatcherJF. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med, 40:376–387. 2006.
4.
AdibhatlaRM, HatcherJF. Role of lipids in brain injury and diseases. Future Lipidol, 2:403–422. 2007.
5.
AdibhatlaRM, HatcherJF. QuinnPJ, WangX. Altered lipid metabolism in brain injury and disorders. Lipids in Health and Disease, 49. New York: Springer-Verlag, 2008; 241–268.
6.
AdibhatlaRM, HatcherJF. Integration of cytokine biology and lipid metabolism in stroke. Front Biosci, 13:1250–1270. 2008.
7.
AdibhatlaRM, HatcherJF. Phospholipase A2, reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Reports, 41:560–567. 2008.
8.
AdibhatlaRM, HatcherJF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: Therapeutic strategies. CNS Neurol Disord Drug Targets, 7:243–253. 2008.
9.
AdibhatlaRM, HatcherJF, DempseyRJ. Phospholipase A2, hydroxyl radicals and lipid peroxidation in transient cerebral ischemia. Antiox Redox Signal, 5:647–654. 2003.
10.
AdibhatlaRM, HatcherJF, DempseyRJ. Lipids and lipidomics in brain injury and diseases. AAPS J, 8:E314–E321. 2006.
11.
AdibhatlaRM, HatcherJF, LarsenEC, ChenX, SunD, TsaoF. CDP-choline significantly restores the phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP-phosphocholine cytidylyltransferase after stroke. J Biol Chem, 281:6718–6725. 2006.
12.
AdibhatlaRM, HatcherJF, SailorKA, DempseyRJ. Polyamines and CNS injury: Spermine and spermidine decrease following transient focal cerebral ischemia in spontaneously hypertensive rats. Brain Res, 938:81–86. 2002.
13.
AgarJ, DurhamH. Relevance of oxidative injury in the pathogenesis of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord, 4:232–242. 2003.
14.
AidS, LangenbachR, BosettiF. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflam, 5:17. 2008.
15.
AkibaS, SatoT. Cellular function of calcium-independent phospholipase A2. Biol Pharm Bull, 27:1174–1178. 2004.
16.
AlamZI, HalliwellB, JennerP. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. J Neurochem, 75:840–846. 2000.
17.
AltamuraS, MuckenthalerMU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis, 16:879–895. 2009.
18.
AndreazzaAC, Kauer–Sant'AnnaM, FreyBN, BondDJ, KapczinskiF, YoungLT, YathamLN. Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord, 111:135–144. 2008.
19.
AntonyJM, van MarleG, OpiiW, ButterfieldDA, MalletF, YongVW, WallaceJL, DeaconRM, WarrenK, PowerC. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci, 7:1088–1095. 2004.
20.
AoyamaT, HidaK, KurodaS, SekiT, YanoS, ShichioheH, IwasakiY. Edaravone (MCI-186) scavenges reactive oxygen species and ameliorates tissue damage in the murine spinal cord injury model. Neurol Med Chir, 48:539–545. 2008.
21.
ArizaM, PueyoR, MatarinMdM, JunqueC, MataroM, ClementeI, MoralP, PocaMA, GarnachoA, SahuquilloJ. Influence of APOE polymorphism on cognitive and behavioural outcome in moderate and severe traumatic brain injury. J Neurol Neurosurg Psychiatry, 77:1191–1193. 2006.
22.
AubourgP.Axons need glial peroxisomes. Nat Genet, 39:936–938. 2007.
BergoMO, YoungSG. Extra Rabs unsnarl a lipid traffic jam. Nat Med, 8:662–664. 2002.
37.
BessardJ, CracowskiJL, Stanke–LabesqueF, BessardG. Determination of isoprostaglandin F2a type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J Chromatogr B Biomed Sci Appl, 754:333–343. 2001.
38.
BessonN, Hullin-MatsudaF, MakinoA, MurateM, LagardeM, PageauxJF, KobayashiT, Delton-VandenbrouckeI. Selective incorporation of docosahexaenoic acid into lysobisphosphatidic acid in cultured THP-1 macrophages. Lipids, 41:189–196. 2006.
39.
BialerM, JohannessenSI, KupferbergHJ, LevyRH, PeruccaE, TomsonT. Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII)Epilepsy Res, 73:1–52. 2007.
40.
BishopA, HobbsKG, EguchiA, JeffreyS, SmallwoodL, PennieC, AndersonJ, EstévezAG. Differential sensitivity of oligodendrocytes and motor neurons to reactive nitrogen species: Implications for multiple sclerosis. J Neurochem, 109:93–104. 2009.
41.
BismuthJ, LinP, YaoQ, ChenC. Ceramide: A common pathway for atherosclerosis?Atherosclerosis, 196:497–504. 2008.
42.
BonifacioMJ, PalmaPN, AlmeidaL, Soares–da-SilvaPS. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Reviews, 13:352–379. 2007.
43.
BonifatiDM, KishoreU. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol, 44:999–1010. 2007.
44.
BonventreJV, HuangZH, TaheriMR, OlearyE, LiE, MoskowitzMA, SapirsteinA. Reduced fertility and postischaemic brain injury in mice deficient in cPLA2. Nature, 390:622–625. 1997.
45.
BoughKJ, RhoJM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia, 48:43–58. 2007.
46.
BoullierA, FriedmanP, HarkewiczR, HartvigsenK, GreenSR, AlmazanF, DennisEA, SteinbergD, WitztumJL, QuehenbergerO. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res, 46:969–976. 2005.
47.
BouvierJ, Zemski BerryKA, Hullin-MatsudaF, MakinoA, MichaudS, GeloenA, MurphyRC, KobayashiT, LagardeM, Delton-VandenbrouckeI. Selective decrease of bis(monoacylglycero)phosphate content in macrophages by high supplementation with docosahexaenoic acid. J Lipid Res, 50:243–255. 2009.
BrasJ, SingletonA, CooksonMR, HardyJ. Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J, 275:5767–5773. 2008.
50.
BrattonDL, HensonPM. Autoimmunity and apoptosis: Refusing to go quietly. Nat Med, 11:26–27. 2005.
51.
BulmerAC, BlanchfieldJT, TothI, FassettRG, CoombesJS. Improved resistance to serum oxidation in Gilbert's syndrome: A mechanism for cardiovascular protection. Atherosclerosis, 199:390–396. 2008.
BurtonNC, KenslerTW, GuilarteTR. In vivo modulation of the Parkinsonian phenotype by Nrf2. NeuroToxicol, 27:1094–1100. 2006.
54.
BushAI, TanziRE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics, 5:421–432. 2008.
55.
CaballeroJ, NahataM. Do statins slow down Alzheimer's disease? A review. J Clin Pharm Ther, 29:209–213. 2004.
56.
CahoonL. The curious case of clioquinol. Nat Med, 15:356–359. 2009.
57.
CalingasanNY, UchidaK, GibsonGE. Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease. J Neurochem, 72:751–756. 1999.
58.
CannonB, ShabalinaIG, KramarovaTV, PetrovicN, NedergaardJ. Uncoupling proteins: A role in protection against reactive oxygen species–or not?Biochim Biophys Acta, 1757:449–458. 2006.
59.
CarlsonNG, RoseJW. Antioxidants in multiple sclerosis: Do they have a role in therapy?CNS Drugs, 20:433–441. 2006.
60.
CaseroRA, PeggAE. Polyamine catabolism and disease. Biochem J, 421:323–338. 2009.
61.
ChangM-K, BinderCJ, MillerYI, SubbanagounderG, SilvermanGJ, BerlinerJA, WitztumJL. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med, 200:1359–1370. 2004.
62.
CharalampopoulosI, RemboutsikaE, MargiorisAN, GravanisA. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab, 19:300–307. 2008.
63.
ChenJ, GrahamSH, NakayamaM, ZhuRL, JinKL, StetlerRA, SimonRP. Apoptosis repressor genes Bcl-2 and Bcl-X-long are expressed in the rat brain following global ischemia. J Cereb Blood Flow Metab, 17:2–10. 1997.
64.
ChenPC, VargasMR, PaniAK, SmeyneRJ, JohnsonDA, KanYW, JohnsonJA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA, 106:2933–2938. 2009.
ChoiS-H, AidS, BosettiF. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: Implications for translational research. Trends Pharmacol Sci, 30:174–181. 2009.
68.
ChoiSM, ChoiK-O, ParkY-K, ChoH, YangEG, ParkH. Clioquinol,a Cu(II)/Zn(II) chelator inhibits both ubiquitination and asparagine hydroxylation of HIF-1alpha, leading to expression of VEGF and EPO in normoxic cells. J Biol Chem, 281:34056–34063. 2006.
69.
ChoudhuryA, DominguezM, PuriV, SharmaDK, NaritaK, WheatleyCL, MarksDL, PaganoRE. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann–Pick C cells. J Clin Invest, 109:1541–1550. 2002.
70.
ClementsCM, McNallyRS, ContiBJ, MakTW, TingJY. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA, 103:15091–15096. 2006.
71.
ClevelJL.A new piece of the ALS puzzle. Nat Genet, 34:357–358. 2003.
72.
CliffordJJ, DragoJ, NatoliAL, WongJYF, KinsellaA, WaddingtonJL, VaddadiKS. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience, 109:81–88. 2002.
73.
CollinoM, PatelNS, ThiemermannC. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis, 2:179–197. 2008.
74.
CommitteeTS.Tirilazad mesylate in acute ischemic stroke : A systematic review. Stroke, 31:2257–2265. 2000.
75.
CrackPJ, TaylorJM. Reactive oxygen species and the modulation of stroke. Free Radic Biol Med, 38:1433–1444. 2005.
DeS, TriguerosMA, KalyvasA, DavidS. Phospholipase A2 plays an important role in myelin breakdown and phagocytosis during Wallerian degeneration. Mol Cell Neurosci, 24:753–765. 2003.
79.
de VriesHE, WitteM, HondiusD, RozemullerAJM, DrukarchB, HoozemansJ, van HorssenJ. Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease?Free Radic Biol Med, 45:1375–1383. 2008.
80.
DeepaD, JayakumariB, ThomasSV. Lipid peroxidation in women with epilepsy. Ann Indian Acad Neurol, 11. 2008.
81.
DegrootA, NomikosGG. In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr Opin Pharmacol, 7:62–68. 2007.
82.
DevlinCM, LeventhalAR, KuriakoseG, SchuchmanEH, WilliamsKJ, TabasI. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol, 28:1723–1730. 2008.
83.
DexterDT, CarterCJ, WellsFR, Javoy-AgidF, AgidY, LeesA, JennerP, MarsdenCD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem, 52:381–389. 1989.
84.
DexterDT, WellsFR, LeesAJ, AgidF, AgidY, JennerP, MarsdenCD. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem, 52:1830–1836. 1989.
85.
DjebailiM, GuoQ, PettusEH, HoffmanSW, SteinDG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma, 22:106–118. 2005.
86.
DonnanGA, DavisSM. Breaking the 3 h barrier for treatment of acute ischaemic stroke. Lancet Neurol, 7:981–982. 2008.
87.
DringenR.Metabolism and functions of glutathione in brain. Prog Neurobiol, 62:649–671. 2000.
88.
Dubois–DalcqM, FeigenbaumV, AubourgP. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci, 22:4–12. 1999.
89.
DupuisL, CorciaP, FerganiA, Gonzalez De AguilarJL, Bonnefont-RousselotD, BittarR, SeilheanD, HauwJJ, LacomblezL, LoefflerJP, MeiningerV. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology, 70:1004–1009. 2008.
90.
DupuisL, OudartH, RenéF, de AguilarJ–LG, LoefflerJ–P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA, 101:11159–11164. 2004.
91.
EhehaltR, KellerP, HaassC, ThieleC, SimonsK. Amyloidogenic processing of the Alzheimer b-amyloid precursor protein depends on lipid rafts. J Cell Biol, 160:113–123. 2003.
92.
ElkindMS.Inflammation, atherosclerosis, and stroke. Neurologist, 12:140–148. 2006.
93.
EmmerlingMR, SpiegelK, WatsonMD. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Immunopharmacology, 38:101–109. 1997.
94.
EmsleyHCA, TyrrellPJ. Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab, 22:1399–1419. 2002.
95.
EstevezAY, PhillisJW. The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. Brain Res, 752:203–208. 1997.
96.
FarooquiAA, HorrocksLA, FarooquiT. Modulation of inflammation in brain: a matter of fat. J Neurochem, 101:577–599. 2007.
97.
FarooquiAA, OngW–Y, HorrocksLA. Inhibitors of brain phospholipase A2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev, 58:591–620. 2006.
98.
FengL, PrestwichGD. 2006. Functional Lipidomics. CRC Press, Taylor & Francis Group: Boca Raton.
99.
FongJJ, RhoneyDH. NXY-059: Review of neuroprotective potential for acute stroke. Ann Pharmacother, 40:461–471. 2006.
100.
ForanE, TrottiD. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal, 11:1587–1602. 2009.
101.
FraislP, AragonesJ, CarmelietP. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov, 8:139–152. 2009.
102.
FraserDD, MorrisonG. Brain oxidative stress after traumatic brain injury … cool it?Crit Care Med, 37:787–788. 2009.
103.
FreyBN, AndreazzaAC, CeresérKMM, MartinsMR, ValvassoriSS, RéusGZ, QuevedoJ, KapczinskiF. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci, 79:281–286. 2006.
104.
FrieboesRM, MoisesHW, GattazWF, YangL, LiT, LiuX, VetterP, MacciardiF, HwuHG, HennF. Lack of association between schizophrenia and the phospholipase-A2 genes cPLA2 and sPLA2. Am J Med Genet, 105:246–249. 2001.
105.
FrolovA, ZielinskiSE, CrowleyJR, Dudley–RuckerN, SchafferJE, OryDS. NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols. J Biol Chem, 278:25517–25525. 2003.
106.
FuY, WangH, HuffTB, ShiR, ChengJ-X.Coherent anti-stokes Raman scattering imaging of myelin degradation reveals a calcium-dependent pathway in lyso-PtdCho-induced demyelination. J Neurosci Res, 85:2870–2881. 2007.
107.
FutermanAH, van MeerG. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol, 5:554–565. 2004.
GarberK.Stroke treatment—Light at the end of the tunnel?Nat Biotech, 25:838–840. 2007.
110.
Garcia–CalvoM, LisnockJ, BullHG, HawesBE, BurnettDA, BraunMP, CronaJH, DavisHRJr., DeanDC, DetmersPA, GrazianoMP, HughesM, MacIntyreDE, OgawaA, O'NeillKA, IyerSPN, ShevellDE, SmithMM, TangYS, MakarewiczAM, UjjainwallaF, AltmannSW, ChapmanKT, ThornberryNA. The target of ezetimibe is Niemann–Pick C1-Like 1 (NPC1L1)Proc Natl Acad Sci USA, 102:8132–8137. 2005.
111.
GardnerAA, ReichertEC, TophamMK, StafforiniDM. Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem, 283:17099–17106. 2008.
112.
GarzaCA, MontoriVM, McConnellJP, SomersVK, KulloIJ, Lopez–JimenezF. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review. Mayo Clin Proc, 82:159–165. 2007.
113.
GasiorM, RogawskiMA, HartmanAL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol, 17:431–439. 2006.
114.
GeY, JensenJH, LuH, HelpernJA, MilesL, IngleseM, BabbJS, HerbertJ, GrossmanRI. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol, 28:1639–1644. 2007.
115.
GemsD, PartridgeL. Stress-response hormesis and aging: “That which does not kill us makes us stronger”Cell Metabolism, 7:200–203. 2008.
116.
GhesquiereSAI, GijbelsMJJ, AnthonsenMW, van GorpPJJ, van der MadeI, JohansenB, HofkerMH, de WintherMJ. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J Lipid Res, 46:201–210. 2005.
117.
GhochikyanA, PetrushinaI, LeesA, VasilevkoV, MovsesyanN, KarapetyanA, AgadjanyanMG, CribbsDH. Ab-immunotherapy for Alzheimer's disease using mannan-amyloid-b peptide immunoconjugates. DNA Cell Biol, 25:571–580. 2006.
118.
GhoshMC, TongW–H, ZhangD, Ollivierre–WilsonH, SinghA, KrishnaMC, MitchellJB, RouaultTA. Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice. Proc Natl Acad Sci USA, 105:12028–12033. 2008.
119.
GilgAG, SinghAK, SinghI. Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. J Neuropathol Exp Neurol, 59:1063–1069. 2000.
120.
Gilgun–SherkiY, MelamedE, OffenD. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J Neurol, 251:261–268. 2004.
121.
Gomez–PinillaF.Brain foods: The effects of nutrients on brain function. Nat Rev Neurosci, 9:568–578. 2008.
122.
Gomez–PinillaF.The influences of diet and exercise on mental health through hormesis. Ageing Res Rev, 7:49–62. 2008.
123.
GoniFM, AlonsoA. Sphingomyelinases: Enzymology and membrane activity. FEBS Lett, 531:38–46. 2002.
124.
GouldSJ, CollinsCS. Peroxisomal–protein import: Is it really that complex?Nat Rev Mol Cell Biol, 3:382–389. 2002.
125.
GreenAR, AshwoodT. Free radical trapping as a therapeutic approach to neuroprotection in stroke: Experimental and clinical studies with NXY-059 and free radical scavengers. Current Drug Targets: CNS Neurol Dis, 4:109–118. 2005.
126.
GreenJT, OrrSK, BazinetRP. The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J Lipid Res, 49:939–944. 2008.
GriffinLD, GongW, VerotL, MellonSH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med, 10:704–711. 2004.
129.
GrimmD.Small silencing RNAs: State-of-the-art. Adv Drug Deliv Rev, 61:672–703. 2009.
130.
GrimmMOW, GrimmHS, PatzoldAJ, ZinserEG, HalonenR, DueringM, TschapeJ-A, StrooperBD, MullerU, ShenJ, HartmannT. Regulation of cholesterol and sphingomyelin metabolism by amyloid-b and presenilin. Nat Cell Biol, 7:1118–1123. 2005.
131.
HallED, BraughlerJM. Free radicals in CNS injury. Res Publ Assoc Res Nerv Ment Dis, 71:81–105. 1993.
132.
HallED, SpringerJE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx, 1:80–100. 2004.
133.
HalliwellB.Oxidative stress and neurodegeneration: Where are we now?J Neurochem, 97:1634–1658. 2006.
134.
HannunYA, ObeidLM. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol, 9:139–150. 2008.
135.
HanssonGK, LibbyP. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol, 6:508–519. 2006.
136.
HardyJ, LewisP, ReveszT, LeesA, Paisan–RuizC. The genetics of Parkinson's syndromes: A critical review. Current Opinion Genet Devel, 19:254–265. 2009.
HatanpaaK, BradyDR, StollJ, RapoportSI, ChandrasekaranK. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann Neurol, 40:411–420. 1996.
139.
HatanpääK, ChandrasekaranK, BradyDR, RapoportSI. No association between Alzheimer plaques and decreased levels of cytochrome oxidase subunit mRNA, a marker of neuronal energy metabolism. Mol Brain Res, 59:13–21. 1998.
140.
HauserRA, ZesiewiczTA. Advances in the pharmacologic management of early Parkinson disease. Neurologist, 13:126–132. 2007.
141.
HayflickSJ.Neurodegeneration with brain iron accumulation: From genes to pathogenesis. Semin Pediat Neurol, 13:182–185. 2006.
142.
HenekaMT, LandrethGE. PPARs in the brain. Biochim Biophys Acta, 1771:1031–1045. 2007.
143.
HerrupK, NeveR, AckermanSL, CopaniA. Divide and die: Cell cycle events as triggers of nerve cell death. J Neurosci, 24:9232–9239. 2004.
144.
HirabayashiT, MurayamaT, ShimizuT. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull, 27:1168–1173. 2004.
145.
HorrobinD. SkinnerER. The lipid hypothesis of schizophrenia. Brain Lipids and Disorders in Biological Psychiatry, 35. Amsterdam: Elsevier Science, 2002; 39–52.
146.
HuwilerA, PfeilschifterJ. Hypoxia and lipid signaling. Biol Chem, 387:1321–1328. 2006.
147.
ImaiK, MoriT, IzumotoH, TakabatakeN, KuniedaT, WatanabeM. Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: A Pilot clinical trial. Neurol Med Chir, 46:373–378. 2006.
JellingerKA.Head injury and dementia. Curr Opin Neurol, 17:719–723. 2004.
154.
JenkinsRW, CanalsD, HannunYA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal, 21:836–846. 2009.
155.
JuS, GreenbergML. Valproate disrupts regulation of inositol responsive genes and alters regulation of phospholipid biosynthesis. Mol Microbiol, 49:1595–1603. 2003.
156.
JuurlinkBJ.Therapeutic potential of dietary phase 2 enzyme inducers in ameliorating diseases that have an underlying inflammatory component. Can J Physiol Pharmacol, 79:266–282. 2001.
157.
KadlA, BochkovVN, HuberJ, LeitingerN. Apoptotic cells as sources for biologically active oxidized phospholipids. Antiox Redox Signal, 6:311–320. 2004.
158.
KaganVE, BayIrHA, BelikovaNA, KapralovO, TyurinaYY, TyurinVA, JiangJ, StoyanovskyDA, WipfP, KochanekPM, GreenbergerJS, PittB, ShvedovaAA, BorisenkoG. Cytochrome c/cardiolipin relations in mitochondria: A kiss of death. Free Radic Biol Med, 46:1439–1453. 2009.
159.
KaganVE, TyurinVA, JiangJ, TyurinaYY, RitovVB, AmoscatoAA, OsipovAN, BelikovaNA, KapralovAA, KiniV, VlasovaII, ZhaoQ, ZouM, DiP, SvistunenkoDA, KurnikovIV, BorisenkoGG. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol, 1:223–232. 2005.
160.
KalyvasA, DavidS. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron, 41:323–335. 2004.
161.
KangKW, LeeSJ, KimSG. Molecualr mechanism of Nrf2 activation by oxidative stress. Antiox Redox Signal, 7:1664–1673. 2005.
162.
KapczinskiF, FreyBN, AndreazzaA, Kauer-Sant'AnnaM, CunhaABM, PostRM. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr, 30:243–245. 2008.
163.
KarishmaKK, HerbertJ. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci, 16:445–453. 2002.
164.
Kauer-Sant'AnnaM, KapczinskiF, AndreazzaAC, BondDJ, LamRW, YoungLT, YathamLN. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol, 12:447–458. 2009.
165.
KavanaghRJ, KamPA. Lazaroids: Efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth, 86:110–119. 2001.
KhannaS, RoyS, ParinandiNL, MaurerM, SenCK. Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol. J Neurochem, 98:1474–1486. 2006.
168.
KhannaS, RoyS, ParkH–A, SenCK. Regulation of c-Src activity in glutamate-induced neurodegeneration. J Biol Chem, 282:23482–23490. 2007.
169.
KhannaS, RoyS, SlivkaA, CraftTKS, ChakiS, RinkC, NotestineMA, DeVriesAC, ParinandiNL, SenCK. Neuroprotective properties of the natural vitamin E a-tocotrienol. Stroke, 36:e144–152. 2005.
170.
KimH–Y. Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem, 282:18661–18665. 2007.
171.
KinnunenPKJ, HolopainenJM. Sphingomyelinase activity of LDL. A link between atherosclerosis, ceramide, and apoptosis?Trends Cardiovasc Med, 12:37–42. 2002.
172.
KinseyGR, CummingsBS, BeckettCS, SaavedraG, ZhangW, McHowatJ, SchnellmannRG. Identification and distribution of endoplasmic reticulum iPLA2. Biochem Biophys Res Commun, 327:287–293. 2005.
173.
KleinJ.Functions and pathophysiological roles of phospholipase D in the brain. J Neurochem, 94:1473–1487. 2005.
KlivenyiP, BealMF, FerranteRJ, AndreassenOA, WermerM, ChinMR, BonventreJV. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J Neurochem, 71:2634–2637. 1998.
KoppakaV, PaulC, MurrayIVJ, AxelsenPH. Early Synergy between Ab 42 and oxidatively damaged membranes in promoting amyloid fibril formation by Ab 40. J Biol Chem, 278:36277–36284. 2003.
178.
KougiasP, ChaiH, LinPH, LumsdenAB, YaoQ, ChenC. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit, 12:RA5–16. 2006.
KronkeM, Adam–KlagesS. Role of caspases in TNF-mediated regulation of cPLA2. FEBS Lett, 531:18–22. 2002.
181.
KunstCB.Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet, 75:933–947. 2004.
182.
KunzA, AnratherJ, ZhouP, OrioM, IadecolaC. Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab, 27:545–551. 2007.
183.
KunzM, GamaCS, AndreazzaAC, SalvadorM, CeresérKM, GomesFA, Belmonte–de–AbreuPS, BerkM, KapczinskiF. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry, 32:1677–1681. 2008.
184.
KurianMA, MorganNV, MacPhersonL, FosterK, PeakeD, GuptaR, PhilipSG, HendrikszC, MortonJEV, KingstonHM, RosserEM, WassmerE, GissenP, MaherER. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN)Neurology, 70:1623–1629. 2008.
185.
LapchakPA, ChapmanDF, NunezSY, ZivinJA. Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: Possible involvement of GABAA receptors. Stroke, 31:1953–1956. 2000.
186.
LaRocheSM.A new look at the second-generation antiepileptic drugs: A decade of experience. Neurologist, 13:133–139. 2007.
187.
LarsenEC, HatcherJF, AdibhatlaRM. Effect of tricyclodecan-9-yl potassium xanthate (D609) on phospholipid metabolism and cell death during oxygen-glucose deprivation in PC12 cells. Neuroscience, 146:946–961. 2007.
188.
LaVauteT, SmithS, CoopermanS, IwaiK, LandW, Meyron–HoltzE, DrakeSK, MillerG, Abu–AsabM, TsokosM, SwitzerR, GrinbergA, LoveP, TresserN, RouaultTA. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet, 27:209–214. 2001.
189.
LaviS, McConnellJP, RihalCS, PrasadA, MathewV, LermanLO, LermanA. Local production of lipoprotein-associated phospholipase A2 and lyso-phosphatidylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation, 115:2715–2721. 2007.
190.
LawMH, CottonRG, BergerGE. The role of phospholipases A2 in schizophrenia. Mol Psychiatry, 11:547–556. 2006.
191.
LeeDW, AndersenJK, KaurD. Iron dysregulation and neurodegeneration: The molecular connection. Mol Interv, 6:89–97. 2006.
192.
LermanA, McConnellJP. Lipoprotein-associated phospholipase A2: A risk marker or a risk factor?Am J Cardiol, 101:S11–S22. 2008.
193.
LetoTL, GeisztM. Role of Nox family NADPH oxidases in host defense. Antioxid Redox Signal, 8:1549–1561. 2006.
194.
LheureuxP, PenalozaA, ZahirS, GrisM. Science review: Carnitine in the treatment of valproic acid-induced toxicity. What is the evidence?Crit Care, 9:431–440. 2005.
195.
LiX, LuL, BushDJ, ZhangX, ZhengL, SuswamEA, KingPH. Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3′-untranslated region. J Neurochem, 108:1032–1044. 2009.
196.
LinD, LeeH–G, LiuQ, PerryG, SmithMA, SayreLM. 4-Oxo-2-nonenal Is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol, 18:1219–1231. 2005.
197.
LinT–N, WangQ, SimonyiA, ChenJ–J, Cheung W–MY, HeY, XuJ, SunAY, HsuCY, SunGY. Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J Neurochem, 90:637–645. 2004.
198.
LinoMM, SchneiderC, CaroniP. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci, 22:4825–4832. 2002.
199.
LiuKJ, RosenbergGA. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med, 39:71–80. 2005.
200.
LiuN–K, ZhangYP, TitsworthWL, JiangXR, HanSK, LuP–H, ShieldsCB, XuX–M. A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol, 59:606–619. 2006.
201.
LiuX, LovellMA, LynnBC. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal Chem, 77:5982–5989. 2005.
202.
LiuXY, LiCY, BuH, LiZ, LiB, SunMM, GuoYS, ZhangL, RenWB, FanZL, WuDX, WuSY. The neuroprotective potential of phase II enzyme inducer on motor neuron survival in traumatic spinal cord injury in vitro. Cell Mol Neurobiol, 28:769–779. 2008.
203.
LothariusJ, BrundinP. Pathogenesis of parkinson's disease: dopamine, vesicles and a-synuclein. Nat Rev Neurosci, 3:932–942. 2002.
204.
LukiwWJ, CuiJ-G, MarcheselliVL, BodkerM, BotkjaerA, GotlingerK, SerhanCN, BazanNG. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest, 115:2774–2783. 2005.
205.
LynchJR, WangH, MaceB, LeinenweberS, WarnerDS, BennettER, VitekMP, McKennaS, LaskowitzDT. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol, 192:109–116. 2005.
206.
MaccarroneM, BattistaN, CentonzeD. The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. Prog Neurobiol, 81:349–379. 2007.
207.
MacDonaldME.Ironing out neurodegeneration: Mutations in a phospholipase A2 cause neurodegenerative diseases with iron accumulation. Clin Genet, 70:306–311. 2006.
208.
MagraneJ, ManfrediG. Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxid Redox Signal, 11:1615–1626. 2009.
209.
MahmoodA, LuD, QuC, GoussevA, ChoppM. Treatment of traumatic brain injury with a combination therapy of marrow stromal cells and atorvastatin in rats. Neurosurgery, 60:546–554. 2007.
210.
MalhotraD, ThimmulappaR, Navas-AcienA, SandfordA, ElliottM, SinghA, ChenL, ZhuangX, HoggJ, PareP, TuderRM, BiswalS. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med, 178:592–604. 2008.
211.
MancusoC.Heme oxygenase and its products in the nervous system. Antioxid Redox Signal, 6:878–887. 2004.
212.
MancusoC, PaniG, CalabreseV. Bilirubin: An endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep, 11:207–213. 2006.
213.
MancusoM, DavidzonG, KurlanRM, TawilR, BonillaE, Di MauroS, PowersJM. Hereditary ferritinopathy: A novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol, 64:280–294. 2005.
MattsonMP, TaubDD. Ancient viral protein enrages astrocytes in multiple sclerosis. Nat Neurosci, 7:1021–1023. 2004.
227.
MaxfieldFR, TabasI. Role of cholesterol and lipid organization in disease. Nature, 438:612–621. 2005.
228.
McCollBW, RothwellNJ, AllanSM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci, 27:4403–4412. 2007.
229.
McLachlanDRC, DaltonAJ. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet, 337:1304–1308. 1991.
230.
McNeillA, BirchallD, HayflickSJ, GregoryA, SchenkJF, ZimmermanEA, ShangH, MiyajimaH, ChinneryPF. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology, 70:1614–1619. 2008.
231.
MehtaSL, ManhasN, RaghubirR. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev, 54:34–66. 2007.
232.
MichalakS, Adamczewska–GoncerzewiczZ, SzczechJ. ATPases and lipid peroxidation in the rat sciatic nerve in the course of experimental neoplastic disease. Expt Mol Pathol, 81:92–99. 2006.
233.
MillerRL, James–KrackeM, SunGY, SunAY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res, 34:55–65. 2009.
234.
MinghettiL.Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol, 63:901–910. 2004.
MohlerERIII, BallantyneCM, DavidsonMH, HanefeldM, RuilopeLM, JohnsonJL, ZalewskiA. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol, 51:1632–1641. 2008.
239.
MoosT, NielsenTR, SkjørringeT, MorganEH. Iron trafficking inside the brain. J Neurochem, 103:1730–1740. 2007.
240.
MorganNV, WestawaySK, MortonJEV, GregoryA, GissenP, SonekS, CangulH, CoryellJ, CanhamN, NardocciN, ZorziG, PashaS, RodriguezD, DesguerreI, MubaidinA, BertiniE, TrembathRC, SimonatiA, SchanenC, JohnsonCA, LevinsonB, WoodsCG, WilmotB, KramerP, GitschierJ, MaherER, HayflickSJ. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet, 38:752–754. 2006.
MurckH, MankuM. Ethyl-EPA in Huntington disease—Potentially relevant mechanism of action. Brain Res Bull, 72:159–164. 2007.
247.
MusiekES, BrooksJD, JooM, BrunoldiE, PortaA, ZanoniG, VidariG, BlackwellTS, MontineTJ, MilneGL, McLaughlinB, MorrowJD. Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the w-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem, 283:19927–19935. 2008.
248.
NakaharaI, KikuchiH, TakiW, NishiS, KitoM, YonekawaY, GotoY, OgataN. Changes in major phospholipids of mitochondria during postischemic reperfusion in rat brain. J Neurosurg, 76:244–250. 1992.
NicoloD, VaradhacharyAS, MonestierM. Atherosclerosis, antiphospholipid syndrome, and antiphospholipid antibodies. Front Biosci, 12:2171–2182. 2007.
251.
NiizumaK, EndoH, ChanPH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem, 109,Suppl 1:133–138. 2009.
Nourooz–ZadehJ, LiuEH, AnggardE, HalliwellB. F4-isoprostanes: A novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA)Biochem Biophys Res Commun, 242:338–344. 1998.
254.
Nourooz–ZadehJ, LiuEH, YhlenB, AnggardEE, HalliwellB. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem, 72:734–740. 1999.
255.
O'CollinsVE, MacleodMR, DonnanGA, HorkyLL, van der WorpBH, HowellsDW. 1,026. Experimental treatments in acute stroke. Ann Neurol, 59:467–477. 2006.
256.
OddoS, BillingsL, KesslakJP, CribbsDH, LaFerlaFM. Ab immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43:321–332. 2004.
257.
OeiH–HS, van der MeerIM, HofmanA, KoudstaalPJ, StijnenT, BretelerMMB, WittemanJM. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam study. Circulation, 111:570–575. 2005.
258.
OgretmenB, HannunYA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Rev Cancer, 4:604–616. 2004.
259.
OhY–K, ParkTG.siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev, 61:850–862. 2009.
260.
OosthuyseB, MoonsL, StorkebaumE, BeckH, NuyensD, BrusselmansK, DorpeJV, HellingsP, GorselinkM, HeymansS, TheilmeierG, DewerchinM, LaudenbachV, VermylenP, RaatH, AckerT, VleminckxV, BoschLVD, CashmanN, FujisawaH, DrostMR, SciotR, BruyninckxF, HicklinDJ, InceC, GressensP, LupuF, PlateKH, RobberechtW, HerbertJ–M, CollenD, CarmelietP. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet, 28:131–138. 2001.
OttM, ZhivotovskyB, OrreniusS. Role of cardiolipin in cytochrome c release from mitochondria. Cell Death Differ, 14:1243–1247. 2007.
264.
PacherP, BatkaiS, KunosG. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev, 58:389–462. 2006.
265.
PannuR, SinghI. Pharmacological strategies for the regulation of inducible nitric oxide synthase: Neurodegenerative versus neuroprotective mechanisms. Neurochem Intl, 49:170–182. 2006.
266.
PapandreouD, PavlouE, KalimeriE, MavromichalisI. The ketogenic diet in children with epilepsy. Br J Nutr, 95:5–13. 2006.
267.
ParkT–S, RoseburyW, KindtEK, KowalaMC, PanekRL. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol Res, 58:45–51. 2008.
268.
PavoineC, PeckerF. Sphingomyelinases: Their regulation and roles in cardiovascular pathophysiology. Cardiovas Res, 82:175–183. 2009.
269.
PenningsM, MeursI, YeD, OutR, HoekstraM, Van BerkelTJC, EckMV. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett, 580:5588–5596. 2006.
270.
PerrinV, DufourN, RaoulC, HassigR, BrouilletE, AebischerP, Luthi–CarterR, DéglonN. Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol, 215:191–200. 2009.
271.
PettusBJ, ChalfantCE, HannunYA. Ceramide in apoptosis: An overview and current perspectives. Biochim Biophys Acta, 1585:114–125. 2002.
272.
PiomelliD, AstaritaG, RapakaR. A neuroscientist's guide to lipidomics. Nat Rev Neurosci, 8:743–754. 2007.
273.
PowersJM.p53-mediated apoptosis, neuroglobin overexpression, and globin deposits in a patient with hereditary ferritinopathy. J Neuropathol Exp Neurol, 65:716–721. 2006.
274.
PramatarovaA, LaganiereJ, RousselJ, BriseboisK, RouleauGA. Neuron-specific sxpression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci, 21:3369–3374. 2001.
275.
ProudfootJ, BardenA, MoriTA, BurkeV, CroftKD, BeilinLJ, PuddeyIB. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem, 272:209–215. 1999.
276.
PuglielliL.Aging of the brain, neurotrophin signaling, and Alzheimer's disease: Is IGF1-R the common culprit?Neurobiol Aging, 29:795–811. 2008.
277.
PurdonAD, RapoportSI. GibsonGE, DienelGA. Energy consumption by phospholipid metabolism in mammalian brain. Brain Energetics: Integration of Molecular and Cellular Processes. New York: Springer, 2007; 401–427.
278.
PurdonAD, RosenbergerTA, ShettyHU, RapoportSI. Energy consumption by phospholipid metabolism in mammalian brain. Neurochem Res, 27:1641–1647. 2002.
QinJ, GoswamiR, BalabanovR, DawsonG. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res, 85:977–984. 2007.
281.
RamiA, BechmannI, StehleJH. Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog Neurobiol, 85:273–296. 2008.
RaoJS, ErtleyRN, DeMarJCJr., RapoportSI, BazinetRP, LeeHJ. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol Psychiatry, 12:151–157. 2007.
284.
RaoJS, ErtleyRN, LeeHJ, DeMarJCJr., ArnoldJT, RapoportSI, BazinetRP. n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry, 12:36–46. 2007.
285.
RaoJS, LeeHJ, RapoportSI, BazinetRP. Mode of action of mood stabilizers: Is the arachidonic acid cascade a common target?Mol Psychiatry, 13:585–596. 2008.
286.
RapoportSI, RaoJS, IgarashiM. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids, 77:251–261. 2007.
RiboniL, VianiP, BassiR, GiussaniP, TettamantiG. Basic fibroblast growth factor-induced proliferation of primary astrocytes. Evidence for the involvement of sphingomyelin biosynthesis. J Biol Chem, 276:12797–12804. 2001.
291.
RiggJL, ZafonteRD. Corticosteroids in TBI: Is the story closed?J Head Trauma Rehabil, 21:285–288. 2006.
292.
RobertsLJ2nd, FesselJP, DaviesSS. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol, 15:143–148. 2005.
293.
RoneMB, FanJ, PapadopoulosV. Cholesterol transport in steroid biosynthesis: Role of protein–protein interactions and implications in disease states. Biochim Biophys Acta, 1791:646–658. 2009.
294.
RosensonRS.Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther, 23:93–101. 2009.
295.
RosensonRS, HislopC, McConnellD, ElliottM, StasivY, WangN, WatersDD. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomised, placebo-controlled trial. The Lancet, 373:649–658. 2009.
296.
RossBM, MamaliasN, MoszczynskaA, RajputAH, KishSJ. Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease. Neuroscience, 102:899–904. 2001.
297.
SamadiP, GrégoireL, RouillardC, BédardPJ, Di PaoloT, LévesqueD. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol, 59:282–288. 2006.
298.
Sanchez–MejiaRO, NewmanJW, TohS, YuG–Q, ZhouY, HalabiskyB, CisseM, Scearce–LevieK, ChengIH, GanL, PalopJJ, BonventreJV, MuckeL. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci, 11:1311–1318. 2008.
299.
SanoM, FukudaK. Activation of mitochondrial biogenesis by hormesis. Circ Res, 103:1191–1193. 2008.
300.
SaverJL.Time is brain—Quantified. Stroke, 37:263–266. 2006.
301.
SayeedI, GuoQ, HoffmanSW, SteinDG. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med, 47:381–389. 2006.
302.
SayreLM, PerryG, HarrisPL, LiuY, SchubertKA, SmithMA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals. J Neurochem, 74:270–279. 2000.
303.
SchafferS, MullerWE, EckertGP. Tocotrienols: Constitutional effects in aging and disease. J Nutr, 135:151–154. 2005.
304.
SchisselSL, SchuchmanEH, WilliamsKJ, TabasI. Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem, 271:18431–18436. 1996.
305.
SchneiderSA, HardyJ, BhatiaK. Iron accumulation in syndromes of neurodegeneration with brain iron accumulation 1 and 2. Causative or consequential?J Neurol Neurosurg Psychiatry:, 80:589–590. 2009.
306.
SchoberA.Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res, 318:215–224. 2004.
307.
SchuchmanEH.The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann–Pick disease. J Inherit Metab Dis, 30:654–663. 2007.
308.
SchulerAM, WoodPA. Mouse models for disorders of mitochondrial fatty acid b-oxidation. ILAR J, 43:57–65. 2002.
309.
SchumacherM, GuennounR, SteinDG, De NicolaAF. Progesterone: Therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther, 116:77–106. 2007.
310.
SchwabC, HosokawaM, McGeerPL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol, 188:52–64. 2004.
311.
SchwartzSL, CaoC, PylypenkoO, RakA, Wandinger–NessA. Rab GTPases at a glance. J Cell Sci, 120:3905–3910. 2007.
312.
SemchukKM, LoveEJ, LeeRG. Parkinson's disease: A test of the multifactorial etiologic hypothesis. Neurology, 43:1173–1180. 1993.
313.
SenCK, KhannaS, RinkC, RoyS, GeraldL. LitwackG. Tocotrienols: The emerging face of natural vitamin E. Vitamins & Hormones, 76. Academic Press, 2007; 203–261.
314.
SenCK, KhannaS, RoyS. Tocotrienols: Vitamin E beyond tocopherols. Life Sci, 78:2088–2098. 2006.
315.
SerhanCN.Resolution phases of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol, 25:101–137. 2007.
316.
SerhanCN, ChiangN, Van DykeTE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol, 8:349–361. 2008.
317.
SerruysPW, Garcia–GarciaHM, BuszmanP, ErneP, VerheyeS, AschermannM, DuckersH, BleieO, DudekD, BotkerHE, von BirgelenC, D'AmicoD, HutchinsonT, ZambaniniA, MastikF, van EsG–A, van der SteenAFW, VinceDG, GanzP, HammCW, WijnsW, ZalewskiA. for the Integrated Biomarker. Imaging StudyI. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation, 118:1172–1182. 2008.
318.
SharonR, Bar–JosephI, FroschMP, WalshDM, HamiltonJA, SelkoeDJ. The formation of highly soluble oligomers of a-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 37:583–595. 2003.
319.
SharpFR, BernaudinM. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci, 5:437–448. 2004.
320.
ShelatPB, ChalimoniukM, WangJ–H, StrosznajderJB, LeeJC, SunAY, SimonyiA, SunGY. Amyloid b peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem, 106:45–55. 2008.
321.
ShibataT, IioK, KawaiY, ShibataN, KawaguchiM, ToiS, KobayashiM, KobayashiM, YamamotoK, UchidaK. Identification of a lipid peroxidation product as a potential trigger of the p53 pathway. J Biol Chem, 281:1196–1204. 2006.
322.
ShimizuE, HashimotoK, OkamuraN, KoikeK, KomatsuN, KumakiriC, NakazatoM, WatanabeH, ShinodaN, OkadaS-i, IyoM. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry, 54:70–75. 2003.
323.
ShinzawaK, SumiH, IkawaM, MatsuokaY, OkabeM, SakodaS, TsujimotoY. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: A model of human neurodegenerative disease. J Neurosci, 28:2212–2220. 2008.
324.
SimmonsDL, BottingRM, HlaT. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev, 56:387–437. 2004.
325.
SimpsonEP, HenryYK, HenkelJS, SmithRG, AppelSH. Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden. Neurology, 62:1758–1765. 2004.
326.
SixDA, DennisEA. The expanding superfamily of phospholipase A2 enzymes: Classification and characterization. Biochim Biophys Acta, 1488:1–19. 2000.
327.
SkeneJHP, ClevelDW. Hypoxia and Lou Gehrig. Nat Genet, 28:107–108. 2001.
328.
SmithC, GrahamDI, MurrayLS, StewartJ, NicollJR. Association of APOE e4 and cerebrovascular pathology in traumatic brain injury. J Neurol Neurosurg Psychiatry, 77:363–366. 2006.
329.
SmithDG, CappaiR, BarnhamKJ. The redox chemistry of the Alzheimer's disease amyloid-b peptide. Biochim Biophys Acta, 1768:1976–1990. 2007.
330.
SmithMA, HarrisPLR, SayreLM, PerryG. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA, 94:9866–9868. 1997.
331.
SongC, ZhaoS. Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: A review of clinical investigations. Expert Opin Investig Drugs, 16:1627–1638. 2007.
332.
SpiteM, SummersL, PorterTF, SrivastavaS, BhatnagarA, SerhanCN. Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. Br J Pharmacol, 2009(in press).
333.
StackEC, SmithKM, RyuH, CormierK, ChenM, HagertySW, Del SignoreSJ, CudkowiczME, FriedlanderRM, FerranteRJ. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta, 1762:373–380. 2006.
334.
StankiewiczJM, BrassSD. Role of iron in neurotoxicity: A cause for concern in the elderly?Curr Opin Clin Nutr Metab Care, 12:22–29. 2009.
335.
SteinDG.Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev, 57:386–397. 2008.
StrieterRM.Masters of angiogenesis. Nat Med, 11:925–927. 2005.
341.
SullivanPG, KrishnamurthyS, PatelSP, PandyaJD, RabchevskyAG. Temporal characterization of mitochondrial bioenergetics after spinal cord injury. J Neurotrauma, 24:991–999. 2007.
342.
SunM–M, BuH, LiB, YuJ–X, GuoY–S, LiC–Y. Neuroprotective potential of phase II enzyme inducer diallyl trisulfide. Neurol Res, 31:23–27. 2009.
343.
SussanTE, JunJ, ThimmulappaR, BedjaD, AnteroM, GabrielsonKL, PolotskyVY, BiswalS. Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS ONE, 3:e3791. 2008.
344.
SuzukiM, WrightLS, MarwahP, LardyHA, SvendsenCN. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA, 101:3202–3207. 2004.
TangY, LiH, LiuJP. Niemann–Pick disease type C: From molecule To clinic. Clin Exp Pharmacol Physiol, 2009(in press).
347.
TaylorLMJr, MonetaGL, SextonGJ, SchuffRA, PorterJM. The Homocysteine, Progression of Atherosclerosis Study Investigators. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg, 29:8–21. 1999.
348.
TemelRE, TangW, MaY, RudelLL, WillinghamMC, IoannouYA, DaviesJP, NilssonL–M, YuL. Hepatic Niemann–Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest, 117:1968–1978. 2007.
TomitoriH, UsuiT, SaekiN, UedaS, KaseH, NishimuraK, KashiwagiK, IgarashiK. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke, 36:2609–2613. 2005.
351.
TrappBD, NaveK-A.Multiple sclerosis: An immune or neurodegenerative disorder?Annu Rev Neurosci, 31:247–269. 2008.
352.
TraynorBJ, BruijnL, ConwitR, BealF, O'NeillG, FaganSC, CudkowiczME. Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurology, 67:20–27. 2006.
353.
TsengY–C, MozumdarS, HuangL. Lipid-based systemic delivery of siRNA. Adv Drug Deliv, 61:721–731. 2009.
354.
UchidaK.4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog Lipid Res, 42:318–343. 2003.
355.
UedaK, ShinoharaS, YagamiT, AsakuraK, KawasakiK. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: A possible involvement of free radicals. J Neurochem, 68:265–271. 1997.
356.
UmemuraK, KatoI, HirashimaY, IshiiY, InoueT, AokiJ, KonoN, OyaT, HayashiN, HamadaH, EndoS, OdaM, AraiH, KinouchiH, HiragaK. Neuroprotective role of transgenic PAF-acetylhydrolase II in mouse models of focal cerebral ischemia. Stroke, 38:1063–1068. 2007.
357.
UrabeT, HattoriN, YoshikawaM, YoshinoH, UchidaK, MizunoY. Colocalization of Bcl-2 and 4-hydroxynonenal modified proteins in microglial cells and neurons of rat brain following transient focal ischemia. Neurosci Lett, 247:159–162. 1998.
358.
UtoT, ContrerasMA, GilgAG, SinghI. Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci, 30:410–418. 2008.
359.
ValianpourF, SelhorstJJM, van LintLEM, van GennipAH, WandersRJA, KempS. Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Mol Genet Metab, 79:189–196. 2003.
van der MostPJ, DolgaAM, NijholtIM, LuitenPGM, EiselUM. Statins: Mechanisms of neuroprotection. Prog Neurobiol, 88:64–75. 2009.
362.
van OijenM, van der MeerIM, HofmanA, WittemanJCM, KoudstaalPJ, BretelerMB. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol, 59:139–144. 2006.
363.
van Roon–MomW, PepersB, t HoenP, VerwijmerenC, den DunnenJ, DorsmanJ, van OmmenG. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease. BMC Mol Biol, 9:84. 2008.
364.
VanceJE.Lipid imbalance in the neurological disorder, Niemann-Pick C disease. FEBS Lett, 580:5518–5524. 2006.
365.
VanceJE, HayashiH, KartenB. Cholesterol homeostasis in neurons and glial cells. Seminars Cell Develop Biol, 16:193–212. 2005.
VoglerS, PahnkeJ, RoussetS, RicquierD, MochH, MirouxB, IbrahimSM. Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis. Am J Pathol, 168:1570–1575. 2006.
371.
WagnerR, HeckmanHM, MyersRR. Wallerian degeneration and hyperalgesia after peripheral nerve injury are glutathione-dependent. Pain, 77:173–179. 1998.
372.
WangJM, JohnstonPB, BallBG, BrintonRD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci, 25:4706–4718. 2005.
373.
WangJM, LiuL, IrwinRW, ChenS, BrintonRD. Regenerative potential of allopregnanolone. Brain Res Rev, 57:398–409. 2007.
374.
WangQ, TangXN, YenariMA. The inflammatory response in stroke. J Neuroimmunol, 184:53–68. 2007.
375.
WebbNR.Getting to the core of atherosclerosis. Nat Med, 14:1015–1016. 2008.
376.
WeinhoferI, Forss–PetterS, ZigmanM, BergerJ. Cholesterol regulates ABCD2 expression: Implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet, 11:2701–2708. 2002.
377.
WelchK, YuanJ. a-Synuclein oligomerization: A role for lipids?Trends Neurosci, 26:517–519. 2003.
378.
WelchKD, DavisTZ, Van EdenME, AustSD. Deleterious iron-mediated oxidation of biomolecules. Free Radic Biol Med, 32:577–583. 2002.
379.
WentworthPJr., NievaJ, TakeuchiC, GalveR, WentworthAD, DilleyRB, DeLariaGA, SavenA, BabiorBM, JandaKD, EschenmoserA, LernerRA. Evidence for ozone formation in human atherosclerotic arteries. Science, 302:1053–1056. 2003.
380.
WheelerD, BandaruVVR, CalabresiPA, NathA, HaugheyNJ. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain, 131:3092–3102. 2008.
381.
WhitfieldJF.Can statins put the brakes on Alzheimer's disease?Expert Opin Investig Drugs, 15:1479–1485. 2006.
382.
WhittonPS.Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol, 150:963–976. 2007.
WilliamsTI, LynnBC, MarkesberyWR, LovellMA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging, 27:1094–1099. 2006.
WoodSJ, YücelM, PantelisC, BerkM. Neurobiology of schizophrenia spectrum disorders: The role of oxidative stress. Ann Acad Med Singapore, 38:396–401. 2009.
389.
WuA, YingZ, Gomez–PinillaF. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma, 21:1457–1467. 2004.
390.
XieC, BurnsDK, TurleySD, DietschyJM. Cholesterol is sequestered in the brains of mice with Niemann–Pick type C disease but turnover is increased. J Neuropathol Exp Neurol, 59:1106–1117. 2000.
391.
XiongY, HallED. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury. Exp Neurol, 216:105–114. 2009.
392.
XuJ, KaoSY, LeeFJ, SongW, JinLW, YanknerBA. Dopamine-dependent neurotoxicity of a-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med, 8:600–606. 2002.
393.
YagamiT, UedaK, AsakuraK, HataS, KurodaT, SakaedaT, TakasuN, TanakaK, GembaT, HoriY. Human group IIA sPLA2 induces neuronal cell death via apoptosis. Mol Pharmacol, 61:114–126. 2002.
394.
YagamiT, UedaK, AsakuraK, NakazatoH, HataS, KurodaT, SakaedaT, SakaguchiG, ItohN, HashimotoY, HoriY. Human group IIA sPLA2 potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels in cultured rat cortical neurons. J Neurochem, 85:749–758. 2003.
395.
YamamotoT, YukiS, WatanabeT, MitsukaM, SaitoKI, KogureK. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res, 762:240–242. 1997.
396.
YanW, WangH–D, HuZ–G, WangQ–F, YinH–X. Activation of Nrf2-ARE pathway in brain after traumatic brain injury. Neurosci Lett, 431:150–154. 2008.
397.
YangL, CalingasanNY, WilleEJ, CormierK, SmithK, FerranteRJ, BealMF. Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem, 109:1427–1439. 2009.
398.
YiF, ZhangAY, JanschaJL, LiP–L, ZouA-P.Homocysteine activates NADH//NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int, 66:1977–1987. 2004.
399.
YoritakaA, HattoriN, UchidaK, TanakaM, StadtmanER, MizunoY. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA, 93:2696–2701. 1996.
400.
YoshidaK, KanekoK, MiyajimaH, TokudaT, NakamuraA, KatoM, IkedaS-i. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci, 175:91–95. 2000.
YoshidaM, TomitoriH, MachiY, KatagiriD, UedaS, HoriguchiK, KobayashiE, SaekiN, NishimuraK, IshiiI, KashiwagiK, IgarashiK. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis, 203:557–562. 2009.
403.
YoungAR, AliC, DureteteA, VivienD. Neuroprotection and stroke: Time for a compromise. J Neurochem, 103:1302–1309. 2007.
404.
YunMR, ImDS, LeeSJ, WooJW, HongKW, BaeSS, KimCD. 4-hydroxynonenal contributes to macrophage foam cell formation through increased expression of class A scavenger receptor at the level of translation. Free Radic Biol Med, 45:177–183. 2008.
405.
ZalewskiA, MacpheeC. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol, 25:923–931. 2005.
406.
ZalewskiA, NelsonJJ, HeggL, MacpheeC. Lp-PLA2: A new kid on the block. Clin Chem, 52:1645–1650. 2006.
